知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

74 records (took 0.044 seconds)

    LEUKEMIA STEM CELL TARGETING LIGANDS AND METHODS OF USE
    1.
    发明申请
    LEUKEMIA STEM CELL TARGETING LIGANDS AND METHODS OF USE 有权
    LEUKEMIA干细胞靶向配体及其使用方法

    公开(公告)号：US20140248633A1

    公开(公告)日：2014-09-04

    申请号：US14130909

    申请日：2012-07-09

    Applicant: Chong-xian Pan ,  Hongyong Zhang

    Inventor： Chong-xian Pan ,  Hongyong Zhang

    IPC: C07K7/06 ,  G01N33/574

    CPC classification number: C07K7/06 ,  A61K47/62 ,  A61K47/6907 ,  A61K51/08 ,  C07K2319/30 ,  G01N33/57426 ,  G01N2333/7056

    Abstract: The present invention is directed to C-type lectin-like molecule-1 (CLL1) specific ligand peptides, comprising the amino acid motif LR(S/T), and methods of their use, e.g., for imaging detection for diagnosis of leukemia and the presence of leukemic stem cells (LSCs) and targeted therapy against leukemia mediated at least in part by CLL1-expressing LSCs.

    Abstract translation: 本发明涉及包含氨基酸基序LR（S / T）的C型凝集素样分子-1（CLL1）特异性配体肽及其使用方法，例如用于诊断白血病的成像检测和 白细胞干细胞（LSCs）的存在和至少部分由CLL1表达的LSCs介导的针对白血病的靶向治疗。

    METHODS FOR USE WITH BAFF ANTAGONISTS
    2.
    发明申请
    METHODS FOR USE WITH BAFF ANTAGONISTS 审中-公开
    使用BAFF拮抗剂的方法

    公开(公告)号：US20140213470A1

    公开(公告)日：2014-07-31

    申请号：US14086352

    申请日：2013-11-21

    Applicant: Genentech, Inc. ,  BIOGEN IDEC MA INC.

    Inventor： Yen-Ming Hsu ,  Leonid Gorelik ,  Tatiana Novobrantseva ,  Joanne Quan ,  Flavius Martin ,  Susan L. Kalled

    IPC: C12Q1/68 ,  G01N33/574 ,  G01N33/564 ,  G01N33/50 ,  G01N33/68

    CPC classification number: C12Q1/6886 ,  C12Q1/6883 ,  C12Q2600/106 ,  G01N33/5041 ,  G01N33/564 ,  G01N33/57426 ,  G01N33/6872 ,  G01N2333/4706 ,  G01N2333/70539 ,  G01N2333/7056 ,  G01N2333/902 ,  G01N2800/52

    Abstract: BAFF plays a central role in acquired immunity. The disclosure identifies BAFF responsive genes that are substantially upregulated by administration of BAFF and substantially downregulated by treatment with a BAFF antagonist. Specific genes are NF-κB2, CD23, H2-Mβ (the beta chain of H2-DM), Fig-1, and OBF-1. The disclosure provides methods and compositions for monitoring the activity of a BAFF antagonist in a mammal; monitoring BAFF activity in a mammal; identifying a mammal to be treated with a BAFF antagonist; and related uses. Such methods include detecting one or more molecules selected from the group consisting of Fig-1 molecule, OBF-1 molecule, and H2-Mβ molecule in a biological sample of the mammal, and optionally further detecting NF-κB2 molecule and/or CD23 molecule in the biological sample.

    Abstract translation: BAFF在获得性免疫中起着核心作用。 本公开确定BAFF反应性基因，其通过施用BAFF基本上调，并且通过用BAFF拮抗剂治疗显着下调。 特定基因是NF-和Kgr; B2，CD23，H2-M＆bgr; （H2-DM的β链），图1和OBF-1。 本公开提供了用于监测哺乳动物中BAFF拮抗剂的活性的方法和组合物; 监测哺乳动物的BAFF活性; 鉴定要用BAFF拮抗剂治疗的哺乳动物; 和相关用途。 这样的方法包括检测选自图1分子，OBF-1分子和H 2 M＆amp; Bgr的一种或多种分子; 分子，并且任选地进一步检测生物样品中的NF-κB分子和/或CD23分子。

    Methods for use with BAFF antagonists
    3.
    发明授权
    Methods for use with BAFF antagonists 有权
    与BAFF拮抗剂一起使用的方法

    公开(公告)号：US08617545B2

    公开(公告)日：2013-12-31

    申请号：US12083614

    申请日：2006-10-12

    Applicant: Yen-Ming Hsu ,  Leonid Gorelik ,  Tatiana Novobrantseva ,  Joanne Quan ,  Flavius Martin ,  Susan L. Kalled

    Inventor： Yen-Ming Hsu ,  Leonid Gorelik ,  Tatiana Novobrantseva ,  Joanne Quan ,  Flavius Martin ,  Susan L. Kalled

    IPC: A61K39/395 ,  A61K38/16 ,  C12Q1/00 ,  C12Q1/68

    CPC classification number: C12Q1/6886 ,  C12Q1/6883 ,  C12Q2600/106 ,  G01N33/5041 ,  G01N33/564 ,  G01N33/57426 ,  G01N33/6872 ,  G01N2333/4706 ,  G01N2333/70539 ,  G01N2333/7056 ,  G01N2333/902 ,  G01N2800/52

    Abstract: BAFF plays a central role in acquired immunity. The disclosure identifies BAFF-responsive genes that are substantially upregulated by administration of BAFF and substantially downregulated by treatment with a BAFF antagonist. Specific genes are: NF-κB2, CD23, H2-Mβ (the beta chain of H2-DM), Fig-1, and OBF-1. The disclosure provides methods and compositions for: monitoring the activity of a BAFF antagonist in a mammal; monitoring BAFF activity in a mammal; identifying a mammal to be treated with a BAFF antagonist; and related uses. Such methods include detecting one or more molecules selected from the group consisting of Fig-1 molecule, OBF-1 molecule, and H2-Mβ molecule in a biological sample of the mammal, and optionally further detecting NF-κB2 molecule and/or CD23 molecule in the biological sample.

    Abstract translation: BAFF在获得性免疫中起着核心作用。 本公开确定通过施用BAFF基本上调的BAFF反应性基因并且通过用BAFF拮抗剂治疗而显着下调。 具体的基因是：NF-κB2，CD23，H2-Mbeta（H2-DM的β链），图1和OBF-1。 本公开提供了用于监测哺乳动物中BAFF拮抗剂的活性的方法和组合物; 监测哺乳动物的BAFF活性; 鉴定要用BAFF拮抗剂治疗的哺乳动物; 和相关用途。 这样的方法包括在哺乳动物的生物样品中检测选自图1分子，OBF-1分子和H2-Mbeta分子的一种或多种分子，并且任选地进一步检测NF-κB2分子和/或CD23分子 在生物样品中。

    HLA-E BINDING
    6.
    发明申请
    HLA-E BINDING 审中-公开
    HLA-E结合

    公开(公告)号：US20080274475A1

    公开(公告)日：2008-11-06

    申请号：US12109990

    申请日：2008-04-25

    Applicant: Veronique M. Braud ,  David S.J. Allan ,  Graham S. Ogg ,  Christopher A. O'Callaghan ,  Andrew J. McMichael

    Inventor： Veronique M. Braud ,  David S.J. Allan ,  Graham S. Ogg ,  Christopher A. O'Callaghan ,  Andrew J. McMichael

    IPC: G01N33/53

    CPC classification number: C07K16/2896 ,  C07K16/2851 ,  C07K2317/76 ,  G01N33/56977 ,  G01N2333/70539 ,  G01N2333/7056

    Abstract: The invention relates to a method of testing a compound for biological activity, which method comprises providing cells expressing one of the CD94/NKG2 family of receptors, contacting the cells with recombinant HLA-E under binding conditions in the presence of the test compound, and determining whether the presence of the compound affects the binding of HLA-E to the cells. The HLA-E property of binding to CD94/NKG2 receptors on NK cells and a subset of CD8+ T cells is useful for targeting CD94/NKG2+ cells for a variety of purposes such as identification, isolation, killing or inactivation.

    Abstract translation: 本发明涉及测试生物活性化合物的方法，该方法包括提供表达CD94 / NKG2受体家族之一的细胞，在测试化合物存在下，在结合条件下将细胞与重组HLA-E接触，以及 确定化合物的存在是否影响HLA-E与细胞的结合。 结合NK细胞上的CD94 / NKG2受体和CD8 + T细胞亚群的HLA-E特性可用于靶向CD94 / NKG2 +细胞用于各种目的，例如鉴定，分离，杀死或灭活。

Patent Agency Ranking